Three-Year Study Confirms Tlando’s Hepatic Safety in American Males with Hypogonadism
Reading Time: 2 minutes Introduction Tlando, an oral testosterone replacement therapy, has been increasingly prescribed to American males suffering from hypogonadism. Given the critical role of the liver in metabolizing drugs, understanding the long-term impact of Tlando on liver function is paramount. This article delves into a comprehensive three-year hepatological study aimed at assessing the hepatic safety of Tlando in American males. Study Design and Methodology The study was conducted over three years, involving 500 American males aged between 30 and 65 years, all diagnosed with hypogonadism and prescribed Tlando. Participants underwent regular liver function tests, including assessments of alanine aminotransferase (ALT), aspartate aminotransferase...


